Test Price
1,000 AED✅ Home Collection Available
Prenatal Delta Beta-Thalassemia Mutation Screening in UAE | 1000 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Our DHA-licensed molecular genetics laboratory delivers Prenatal Delta Beta-Thalassemia Mutation Screening with 99.9% diagnostic sensitivity via ISO 9001:2015 certified End Point PCR methodology. This DNA-based assay identifies specific deletions in the HBB gene cluster from amniotic fluid, chorionic villi, or peripheral blood, providing definitive results within 5–6 calendar days to guide critical reproductive decisions. All invasive sample collections are performed strictly within accredited hospital facilities. Post-test telephonic genetic counselling is included for result interpretation and family risk assessment.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Clinical Guidance: Telephonic Post-Test Genetic Counselling for result interpretation by a qualified Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
- Sample Integrity: Hospital Extraction Only – invasive specimen collection conducted within accredited facilities; mobile home phlebotomy is disabled for safety.
Test Overview & Methodology
Prenatal Delta Beta-Thalassemia Mutation Screening employs End Point PCR to detect large deletions within the HBB gene cluster on chromosome 11 that cause delta-beta thalassemia, a hereditary hemoglobinopathy characterized by hypochromic microcytic anemia. The assay delivers greater than 99% analytical sensitivity for the targeted deletion loci. Accepted specimens include amniotic fluid obtained via amniocentesis, chorionic villi obtained via CVS, or peripheral blood for maternal carrier screening. All invasive collections are performed under ultrasound guidance by a qualified obstetrician within a hospital setting. Results are reported within 5–6 calendar days and include a detailed interpretive report from our Consultant Medical Geneticist.
| Test Feature | Our Test (ISO Lab) | Closest Alternative |
|---|---|---|
| Precision & Method | End Point PCR specifically targeting delta‑beta deletions; >99% analytical sensitivity | Sanger sequencing or unvalidated NGS panels; may miss large deletions |
| Turnaround Time | 5–6 calendar days | 10–14 days or more |
| Regulatory Compliance | DHA-licensed facility (License 1143), ISO 9001:2015, UAE PDPL & Health Data Protection Laws | May lack UAE-specific quality accreditation |
| Sample Acceptability | Amniotic fluid, chorionic villi, or peripheral blood; hospital extraction only for invasive samples | Often limited to fresh blood; no invasive specimen handling protocols |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist with expertise in hemoglobinopathy diagnostics, I emphasize that this targeted deletion assay delivers the molecular clarity needed for informed reproductive counselling. The result must be interpreted within the full clinical context of the couple’s carrier status, family pedigree, and haematological indices. Early detection empowers families to make thoughtful decisions, but no single test replaces comprehensive genetic counselling and multidisciplinary care.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory Precautions for Genetic Screening
Important Clinical Advisory
Genetic screening results provide probabilistic risk information and must never replace independent clinical judgment. Patients are advised to discuss all findings with their obstetrician and a qualified genetic counsellor before making any reproductive decisions. Do not alter or discontinue any prescribed therapy based solely on screening results without consulting your treating physician.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent; active maternal intrauterine or systemic infection; uncorrected coagulopathy; multiple gestation with incompatible sampling route.
- ER Red Flags After Sampling: Sudden severe abdominal pain, heavy vaginal bleeding, persistent fever >38°C, or leakage of amniotic fluid—seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is Prenatal Delta Beta-Thalassemia Mutation Screening?
This targeted molecular assay analyzes fetal or parental DNA for specific large deletions in the HBB gene cluster that cause delta‑beta thalassemia. It is used for prenatal diagnosis and carrier detection to inform reproductive planning, differentiate from other thalassemia syndromes, and guide genetic counselling.
2. How is the sample collected for this test?
For fetal diagnosis, amniotic fluid is obtained via amniocentesis or chorionic villi via CVS under continuous ultrasound guidance by a qualified obstetrician within a hospital setting. For maternal carrier screening, a standard peripheral blood draw can be used. All invasive procedures are hospital‑extraction only; mobile home phlebotomy is disabled for safety.
3. When will I receive my results and what do they mean?
Results are available within 5–6 calendar days. A positive result indicates the presence of a homozygous or compound heterozygous deletion consistent with delta‑beta thalassemia disease or carrier trait. A negative result confirms absence of the targeted deletions. Our Consultant Medical Geneticist provides a detailed interpretive report and telephonic counselling to explain implications for the fetus and family.
4. Does insurance cover this screening?
Coverage varies by insurer and policy. We offer direct billing verification via WhatsApp at +971 54 548 8731. Our team will check your eligibility and provide a pre‑authorization estimate before sample collection.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance Framework
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling, storage, and processing. Additionally, we comply with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields to ensure secure digital health data exchange. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory is ISO 9001:2015 certified, and all genetic counselling services are provided by DHA‑licensed practitioners.
Clinical & Logistical Metadata
| Test Name | Prenatal Delta Beta-Thalassemia Mutation Screening |
| Price (AED) | 1,000 AED |
| Turnaround Time | 5–6 calendar days |
| Sample Type / Matrix | Amniotic fluid, Chorionic villi, or Peripheral blood – Hospital Extraction Only for invasive samples; mobile home phlebotomy disabled for safety |
| Methodology Used | End Point PCR targeting HBB gene cluster deletions |
| ICD-10-CM Code | D56.8 |
| LOINC Code | 21637-2 |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians